ArticleMammalian genome : official journal of the International Mammalian Genome Society2026
Multi-omics integration and machine learning define an iron-sulfur cluster/zinc-binding protein prognostic signature in esophageal squamous cell carcinoma.
Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Esophageal squamous cell carcinoma (ESCC) is characterized by substantial intratumoral heterogeneity and poor clinical prognosis. Although metalloproteins are well-documented to drive ESCC malignant progression, incomplete functional annotation of this protein family significantly impedes the clinical translation of related research outcomes. This study reports the development and validation of a reliable prognostic model via integrating AlphaFold2-predicted iron-Sulfur (Fe-S) Cluster/Zinc (Zn)-binding proteins with ESCC multi-omics data. Nine differentially expressed AlphaFold2-predicted Fe-S/Zn-binding proteins significantly associated with ESCC prognosis were identified through integrated analysis of multi-omics and clinical data from public datasets and independent ESCC cohorts. After systematic evaluation of 117 machine learning combinations, a three-Fe-S/Zn-binding protein Prognostic Signature (FZPS) comprising YPEL5, MIB1 and ELAC2 was constructed, and validated as an independent predictor of poor overall survival across cohorts. High FZPS risk correlates with an immune-excluded, stress-adaptive phenotype with p21-driven inflammation and intrinsic immunotherapy resistance, while low-FZPS tumors harbor more actionable mutations and exhibit enhanced sensitivity to targeted therapy and immunotherapy. In vitro assays confirmed YPEL5 knockdown markedly suppresses ESCC cell viability, proliferation and migration. In conclusion, FZPS is a reliable independent prognostic biomarker guiding precision oncology practice for ESCC.
Indexed as
Identifiers
42637882What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.